Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
for PDAC
Sites in Rochester +17 more locations
Sponsor: Tango Therapeutics, Inc.
Sex: All·Age: 18+
Code: NCT06922591·Phase 1, Phase 2·Recruiting·Listed Apr 2025